Since the Cleveland Clinic reached its $308,000 DOJ settlement and agreed to a 20-year ban on pediatric gender procedures — reported here June 9 — a second institution has been forced to act. Texas Children's Hospital in Houston is moving to open what would be the nation's first clinic dedicated exclusively to detransition care, according to the New York Post, after Texas Attorney General Ken Paxton investigated the hospital for allegedly violating the state's ban on gender procedures for minors.

The Scale of the Problem

The advocacy group Do No Harm — where Dr. Andre Van Mol is a senior fellow — analyzed insurance claims and documented nearly 14,000 U.S. child gender-transition patients between 2019 and 2023, according to the New York Post. The Children's Hospital of Philadelphia performed sex-change treatments, including surgeries, on over 120 minors. Boston Children's Hospital treated more than 300.

Now some of those patients are adults who regret those interventions. Until recently, the hospitals that treated them had largely refused to provide detransition care or even acknowledge detransitioners as a legitimate patient population.

Why Hospitals Have Stonewalled

The New York Post quotes Van Mol directly on why medical professionals have avoided this: they are terrified of activists. Clinicians who even acknowledge detransition as a valid medical path risk targeted online campaigns against their hospitals and careers. That's an on-record statement from a practicing physician about the real-world chilling effect on clinical decisions.

If political and activist pressure can push hospitals to provide gender procedures to minors, it can also pressure those same hospitals to abandon those patients afterward. The incentive structure is broken in both directions.

The Case for Gender-Affirming Care

Major medical organizations including the American Academy of Pediatrics maintain that gender-affirming care, when properly administered with informed consent, produces better mental health outcomes for transgender youth. Their position is that regret rates are low, that detransitioners represent a small minority, and that restricting access causes measurable harm to a larger population.

Those studies are now being scrutinized heavily. Sweden, Finland, and the UK's NHS have all materially restricted pediatric gender medicine over the last three years after conducting systematic evidence reviews. The UK's Cass Review — an independent four-year examination commissioned by the NHS — concluded in April 2024 that the evidence base for puberty blockers and hormones in minors was remarkably weak. The American institutional consensus is increasingly an outlier internationally.

Regardless of the original treatment, once a patient presents and says they want to reverse course, ignoring them raises basic ethical questions that cannot be avoided.

What Mainstream Coverage Is Missing

Center-left outlets have covered the Cleveland Clinic settlement primarily through a civil-liberties frame — restrictions on gender care as government overreach. That framing largely skips over the detransition care component, which is significant in both the settlement and the Texas Children's Hospital move.

Center-right coverage has been stronger on the detransitioner angle but has sometimes framed every involved clinician as a bad actor. Many physicians who provided these treatments believed they were helping. The question going forward is whether the medical system will correct course and care for the patients it has left behind.

What Comes Next

As of June 10, 2026, no national registry of detransition patients exists. No major medical association has issued clinical guidelines for detransition care. The Cleveland Clinic settlement terms and the Texas Children's Hospital clinic are essentially building the field from scratch.

Two hospitals, both under legal pressure, are now doing what hundreds of institutions should have done years ago: treating patients who need help. The patients didn't ask for this fight. They just want care.